August 10, 2020
Tag: Exhibitor Webinar , VEC , CPHI China
Company Name: Xiamen Amoytop Biotech Co., Ltd.
Company Profile: Xiamen Amoytop Biotech Co., Ltd. was set up in 1996, specializing in development and research on genetic engineering technology and working on the industrialization of biological pharmacy. It is a high-tech enterprise that combines R&D, manufacture, marketing and sales.
Amoytop Biotech has a CNAS accredited laboratory. Since 1997, through cooperating with the National Institutes for Food and Drug Control (NIFDC), Amoytop Biotech has developed a series of national standards of recombinant protein drugs, such as rHuGM-CSF, rHuG-CSF, rHuIL-11, rHuIFN α-2a, rHuIFN α-2b, etc., and has become the main provider of national standards of recombinant protein drugs for NIFDC.
Based on the professional R&D ability and advanced technology platform, Amoytop Biotech has marketed three recombinant protein drugs including rHuGM-CSF, rHuG-CSF and rHuIL-11. In 2016, Amoytop Biotech launched Y-shape pegylated interferon alfa 2b, the first China-made interferon drug with international patents. In addition, there are several innovative patented drugs in different clinical stages. Amoytop Biotech, as a leading enterprise on exporting recombinant protein drugs in China, has passed GMP inspections from several countries\' health authorities, including Pakistan, Brazil, and Russia, etc.
Amoytop Biotech will continue to focus its work on genetically engineered products, and strive to become a world-class professional enterprise supplying the therapeutic biotechnological products.
Title:Supplier of Recombinant protein products
Speaker : Ally Luo
Position:Senior Supervisor of International Regulatory
Licensed pharmacist;
Over 9 years experience in international regulatory affairs.
For more information, click here to view my store.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: